Product Center
HRK-X Selected for Jiangsu Province's 2024 Innovative Pharmaceutical Equipment Special Award List!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-03-08
- Views:
(Summary description)Recently, the list of innovative drug and device award projects of the special fund for the construction of a strong manufacturing province in Jiangsu Province in 2024 was released, Ab&B Bio-Tech CO.,LTD. JS's self-developed quadrivalent influenza virus subunit vaccine (HRK-X), a new class of drugs, was selected into the list of approved innovative drugs in 2023.
HRK-X Selected for Jiangsu Province's 2024 Innovative Pharmaceutical Equipment Special Award List!
(Summary description)Recently, the list of innovative drug and device award projects of the special fund for the construction of a strong manufacturing province in Jiangsu Province in 2024 was released, Ab&B Bio-Tech CO.,LTD. JS's self-developed quadrivalent influenza virus subunit vaccine (HRK-X), a new class of drugs, was selected into the list of approved innovative drugs in 2023.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-03-08 16:20
- Views:
Recently, the list of innovative drug and device award projects of the special fund for the construction of a strong manufacturing province in Jiangsu Province in 2024 was released, Ab&B Bio-Tech CO.,LTD. JS's self-developed quadrivalent influenza virus subunit vaccine (HRK-X), a new class of drugs, was selected into the list of approved innovative drugs in 2023.
As a preventive Category 1 biological product, HRK-X features a proprietary influenza virus subunit extraction process. This technology not only ensures the high purity of HA and NA proteins from all four vaccine strains and vaccine safety, but also demonstrates excellent immunogenicity. The product's quality standards exceed both Chinese Pharmacopoeia and EU Pharmacopoeia requirements, filling a domestic gap in this field!
Recently, at the Entrepreneurship Spirit Promotion Conference for Advancing New Industrialization, the Pharmaceutical High-Tech Zone (Gaogang District) awarded Mr. An Youcai, Chairman and General Manager of Ab&B Bio-Tech Co., Ltd., the honorary title of "Top Ten Star Entrepreneurs"! This recognition fully acknowledges Mr. An's and Ab&B Bio's pioneering spirit in developing and industrializing innovative human vaccines - their boldness to venture and innovate!
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
